| 0.008 |
squamous cell carcinoma |
NA |
BeFree,GAD |
|
Detail |
| 0.005 |
Chromosome Aberrations |
NA |
GAD |
|
Detail |
| 0.002 |
Congenital chromosomal disease |
NA |
BeFree |
|
Detail |
| 0.002 |
Colonic Neoplasms |
NA |
GAD |
|
Detail |
| 0.002 |
Colonic Polyps |
NA |
GAD |
|
Detail |
| 0.002 |
colorectal carcinoma |
NA |
BeFree |
|
Detail |
| 0.013 |
Colorectal Neoplasms |
NA |
GAD,LHGDN |
|
Detail |
| 0.002 |
Connective Tissue Diseases |
NA |
GAD |
|
Detail |
| <0.001 |
Coronary heart disease |
NA |
BeFree |
|
Detail |
| 0.003 |
Crohn Disease |
NA |
BeFree,GAD |
|
Detail |
| 0.002 |
Deafness |
NA |
GAD |
|
Detail |
| <0.001 |
Diabetes Mellitus, Non-Insulin-Dependent |
NA |
BeFree |
|
Detail |
| 0.021 |
DNA Damage |
NA |
GAD |
|
Detail |
| 0.001 |
eclampsia |
NA |
BeFree |
|
Detail |
| 0.010 |
Pathological accumulation of air in tissues |
NA |
GAD,LHGDN |
|
Detail |
| 0.002 |
endometriosis |
NA |
GAD |
|
Detail |
| 0.006 |
epilepsy |
NA |
BeFree,GAD |
|
Detail |
| 0.009 |
Esophageal Neoplasms |
Association between esophageal cancer risk and EPHX1 polymorphisms: a meta-analy... |
BeFree,GAD |
24803829 |
Detail |
| 0.009 |
Esophageal Neoplasms |
Lack of association between EPHX1 polymorphism and esophageal cancer risk: evide... |
BeFree,GAD |
25714851 |
Detail |
| 0.002 |
Fetal Diseases |
NA |
GAD |
|
Detail |
| 0.007 |
Head and Neck Neoplasms |
NA |
GAD |
|
Detail |
| 0.002 |
Hearing Loss, Partial |
NA |
GAD |
|
Detail |
| 0.005 |
hepatitis |
NA |
BeFree,GAD |
|
Detail |
| <0.001 |
hepatitis A |
NA |
BeFree |
|
Detail |
| <0.001 |
hepatitis B |
NA |
BeFree |
|
Detail |
| 0.006 |
hepatitis C |
NA |
BeFree,GAD,LHGDN |
|
Detail |
| 0.007 |
Hodgkin Disease |
NA |
GAD |
|
Detail |
| 0.002 |
Hypercapnia |
NA |
GAD |
|
Detail |
| 0.002 |
pulmonary hypertension |
NA |
GAD |
|
Detail |
| 0.005 |
Inflammation |
NA |
GAD |
|
Detail |
| 0.007 |
Laryngeal neoplasm |
NA |
GAD,LHGDN |
|
Detail |
| <0.001 |
leukemia |
NA |
BeFree |
|
Detail |
| 0.002 |
chronic lymphocytic leukemia |
NA |
GAD |
|
Detail |
| <0.001 |
Acute lymphocytic leukemia |
NA |
BeFree |
|
Detail |
| <0.001 |
Leukemia, Lymphocytic, Acute, L1 |
NA |
BeFree |
|
Detail |
| 0.005 |
Leukemia, Myelocytic, Acute |
NA |
BeFree,GAD |
|
Detail |
| <0.001 |
Liver diseases |
NA |
BeFree |
|
Detail |
| <0.001 |
Alcoholic Liver Diseases |
NA |
BeFree |
|
Detail |
| 0.005 |
Liver neoplasms |
NA |
GAD |
|
Detail |
| 0.170 |
Chronic Obstructive Airway Disease |
NAC treatment in COPD patients with extremely slow/slow EPHX1 enzyme activity im... |
BeFree,CTD_human,GAD,LHGDN |
25999707 |
Detail |
| 0.138 |
Lung Neoplasms |
NA |
CTD_human,GAD,LHGDN |
|
Detail |
| 0.125 |
lymphoma |
NA |
BeFree,CTD_human,GAD |
|
Detail |
| 0.129 |
Lymphoma, Non-Hodgkin |
NA |
CTD_human,GAD |
|
Detail |
| 0.003 |
Malignant neoplasm of stomach |
NA |
BeFree,GAD |
|
Detail |
| 0.120 |
Animal Mammary Neoplasms |
NA |
CTD_human |
|
Detail |
| 0.120 |
Mammary Neoplasms, Experimental |
NA |
CTD_human |
|
Detail |
| 0.002 |
Mesothelioma |
NA |
GAD |
|
Detail |
| 0.007 |
Mouth Neoplasms |
NA |
GAD |
|
Detail |
| 0.126 |
multiple myeloma |
NA |
BeFree,CTD_human,GAD |
|
Detail |
| 0.002 |
Musculoskeletal Diseases |
NA |
GAD |
|
Detail |
| 0.003 |
myocardial infarction |
NA |
BeFree,GAD |
|
Detail |
| 0.002 |
Occupational Diseases |
NA |
GAD |
|
Detail |
| 0.002 |
Oropharyngeal Neoplasms |
NA |
GAD |
|
Detail |
| 0.001 |
ovarian carcinoma |
NA |
BeFree |
|
Detail |
| 0.005 |
Parkinson disease |
NA |
GAD |
|
Detail |
| 0.120 |
Peripheral neuropathy |
NA |
CTD_human |
|
Detail |
| 0.005 |
Pharyngeal Neoplasms |
NA |
GAD |
|
Detail |
| 0.002 |
Pleural Neoplasms |
NA |
GAD |
|
Detail |
| 0.002 |
pneumonia |
NA |
GAD |
|
Detail |
| 0.005 |
polycystic ovary syndrome |
NA |
BeFree,GAD |
|
Detail |
| 0.135 |
pre-eclampsia |
NA |
CTD_human,GAD,LHGDN |
|
Detail |
| 0.002 |
Pregnancy Complications, Hematologic |
NA |
GAD |
|
Detail |
| 0.120 |
Prostatic Neoplasms |
NA |
CTD_human |
|
Detail |
| 0.122 |
pulmonary emphysema |
NA |
BeFree,CTD_human |
|
Detail |
| 0.003 |
Respiratory Tract Diseases |
NA |
BeFree,GAD |
|
Detail |
| 0.002 |
Dermatologic disorders |
NA |
GAD |
|
Detail |
| 0.002 |
Stomach Neoplasms |
NA |
GAD |
|
Detail |
| 0.002 |
thrombosis |
NA |
GAD |
|
Detail |
| 0.002 |
Tobacco use disorder |
NA |
GAD |
|
Detail |
| <0.001 |
Wheezing |
NA |
BeFree |
|
Detail |
| <0.001 |
diffuse large B-cell lymphoma |
NA |
BeFree |
|
Detail |
| 0.002 |
Alcohol abuse |
NA |
GAD |
|
Detail |
| <0.001 |
Squamous cell carcinoma of lung |
NA |
BeFree |
|
Detail |
| 0.009 |
Premature Birth |
NA |
GAD |
|
Detail |
| 0.004 |
esophageal carcinoma |
Association between esophageal cancer risk and EPHX1 polymorphisms: a meta-analy... |
BeFree,GAD |
24803829 |
Detail |
| 0.004 |
esophageal carcinoma |
Lack of association between EPHX1 polymorphism and esophageal cancer risk: evide... |
BeFree,GAD |
25714851 |
Detail |
| 0.002 |
Malignant neoplasm of brain |
NA |
GAD |
|
Detail |
| 0.066 |
Malignant neoplasm of lung |
However, only four of the previously reported associations with polymorphisms in... |
BeFree |
18258609 |
Detail |
| 0.009 |
Carcinoma of lung |
However, only four of the previously reported associations with polymorphisms in... |
BeFree |
18258609 |
Detail |
| <0.001 |
childhood brain tumor |
NA |
BeFree |
|
Detail |
| 0.002 |
alpha 1-antitrypsin deficiency |
NA |
GAD |
|
Detail |
| 0.120 |
Amphetamine-Related Disorders |
NA |
CTD_human |
|
Detail |
| <0.001 |
Bulla of lung |
NA |
BeFree |
|
Detail |
| 0.066 |
Malignant neoplasm of lung |
Impact of epoxide hydrolase 1 polymorphisms on lung cancer susceptibility in Asi... |
BeFree,GAD |
25312477 |
Detail |
| 0.005 |
age related macular degeneration |
NA |
BeFree,GAD |
|
Detail |
| <0.001 |
Childhood asthma |
NA |
BeFree |
|
Detail |
| <0.001 |
Acquired aplastic anemia |
NA |
BeFree |
|
Detail |
| 0.008 |
Cancer of Head and Neck |
Systematic Review and Meta-Analysis of the Relationship between EPHX1 Polymorphi... |
BeFree,GAD |
25923690 |
Detail |
| 0.001 |
Squamous cell carcinoma of esophagus |
NA |
BeFree |
|
Detail |
| 0.002 |
cervix carcinoma |
NA |
GAD |
|
Detail |
| 0.002 |
Malignant neoplasm of liver |
NA |
GAD |
|
Detail |
| 0.003 |
malignant mesothelioma |
NA |
BeFree,GAD |
|
Detail |
| 0.008 |
Malignant neoplasm of prostate |
NA |
BeFree,GAD |
|
Detail |
| <0.001 |
Craniofacial Abnormalities |
NA |
BeFree |
|
Detail |
| 0.002 |
neuropathy |
NA |
GAD |
|
Detail |
| 0.002 |
Hepatitis B, Chronic |
NA |
GAD |
|
Detail |
| 0.002 |
Hepatitis C, Chronic |
NA |
GAD |
|
Detail |
| 0.016 |
Malignant neoplasm of esophagus |
Association between esophageal cancer risk and EPHX1 polymorphisms: a meta-analy... |
BeFree,GAD |
24803829 |
Detail |
| 0.016 |
Malignant neoplasm of esophagus |
Lack of association between EPHX1 polymorphism and esophageal cancer risk: evide... |
BeFree,GAD |
25714851 |
Detail |
| <0.001 |
Carcinoma of larynx |
NA |
BeFree |
|
Detail |
| 0.002 |
Carcinogenesis |
NA |
BeFree |
|
Detail |
| 0.001 |
prostate carcinoma |
NA |
BeFree |
|
Detail |
| 0.003 |
Epithelial ovarian cancer |
NA |
BeFree,GAD |
|
Detail |
| <0.001 |
breast carcinoma |
NA |
BeFree |
|
Detail |
| 0.009 |
Carcinoma of lung |
Impact of epoxide hydrolase 1 polymorphisms on lung cancer susceptibility in Asi... |
BeFree |
25312477 |
Detail |
| <0.001 |
colon carcinoma |
NA |
BeFree |
|
Detail |
| <0.001 |
stomach carcinoma |
NA |
BeFree |
|
Detail |
| <0.001 |
Carcinoma of bladder |
NA |
BeFree |
|
Detail |
| 0.002 |
Perinatal death |
NA |
GAD |
|
Detail |
| <0.001 |
Severe chronic obstructive pulmonary disease |
NA |
BeFree |
|
Detail |
| 0.002 |
Pregnancy associated hypertension |
NA |
GAD |
|
Detail |
| <0.001 |
Carcinogenicity |
NA |
BeFree |
|
Detail |
| 0.003 |
Optic Atrophy, Hereditary, Leber |
NA |
LHGDN |
|
Detail |
| 0.003 |
ovarian neoplasm |
NA |
BeFree,LHGDN |
|
Detail |
| 0.002 |
Genomic Instability |
NA |
GAD |
|
Detail |
| 0.002 |
Microsatellite Instability |
NA |
GAD |
|
Detail |
| <0.001 |
Polyp of large intestine |
NA |
BeFree |
|
Detail |
| 0.004 |
Malignant neoplasm of ovary |
NA |
BeFree,GAD |
|
Detail |
| 0.002 |
Mesothelioma (malignant, clinical disorder) (disorder) |
NA |
GAD |
|
Detail |
| 0.001 |
Adenoma of large intestine |
NA |
BeFree |
|
Detail |
| <0.001 |
Hypopharyngeal Carcinoma |
NA |
BeFree |
|
Detail |
| 0.002 |
hearing impairment |
NA |
GAD |
|
Detail |
| 0.120 |
Micronuclei, Chromosome-Defective |
NA |
CTD_human |
|
Detail |
| 0.002 |
Mammary Neoplasms |
NA |
GAD |
|
Detail |
| 0.033 |
colorectal cancer |
NA |
BeFree,GAD |
|
Detail |
| 0.002 |
Cirrhosis |
NA |
GAD |
|
Detail |
| 0.240 |
Hypercholanemia, familial |
NA |
CLINVAR,ORPHANET |
|
Detail |
| 0.125 |
Precursor Cell Lymphoblastic Leukemia Lymphoma |
NA |
BeFree,CTD_human,GAD |
|
Detail |
| 0.136 |
liver carcinoma |
NA |
BeFree,CTD_human,GAD,LHGDN |
|
Detail |
| <0.001 |
Oropharyngeal Carcinoma |
NA |
BeFree |
|
Detail |
| 0.005 |
WARFARIN SENSITIVITY (disorder) |
NA |
GAD |
|
Detail |
| 0.002 |
Infection |
NA |
GAD |
|
Detail |
| 0.002 |
Hearing Loss |
NA |
GAD |
|
Detail |
| <0.001 |
Congenital Abnormality |
NA |
BeFree |
|
Detail |
| 0.002 |
Abruptio Placentae |
NA |
GAD |
|
Detail |
| 0.013 |
adenoma |
NA |
BeFree,GAD,LHGDN |
|
Detail |
| <0.001 |
anemia |
NA |
BeFree |
|
Detail |
| 0.002 |
Anoxia |
NA |
GAD |
|
Detail |
| 0.006 |
asthma |
NA |
BeFree,GAD |
|
Detail |
| 0.008 |
Malignant neoplasm of urinary bladder |
NA |
BeFree,GAD |
|
Detail |
| 0.003 |
Bladder Neoplasm |
NA |
LHGDN |
|
Detail |
| 0.003 |
Bone Diseases |
NA |
BeFree,GAD |
|
Detail |
| <0.001 |
Brain Neoplasms |
NA |
BeFree |
|
Detail |
| 0.010 |
Malignant neoplasm of breast |
NA |
BeFree,GAD |
|
Detail |
| 0.003 |
bronchitis |
NA |
BeFree,GAD |
|
Detail |
| <0.001 |
Malignant tumor of colon |
NA |
BeFree |
|
Detail |
| 0.003 |
Malignant neoplasm of larynx |
NA |
BeFree,GAD |
|
Detail |
| <0.001 |
Non-small cell lung carcinoma |
NA |
BeFree |
|
Detail |
